PES 2025 15 - 18 May 2025

Preference of somapacitan pen-injector or lonapegsomatropin autoinjector, reported by participants with growth-related disorders and caregivers

Authors :

Johan Medina¹; Gitte Ter-Borch²; Nicky Kelepouris³; Sophie Hamilton³; Maya Gonczi⁴; Jørgen Vinsløv Hansen⁵; Shahid Akhtar¹

Affiliations

View Details Hide Details

Keywords

Rare Endocrine Disorder

Congress poster

Somapacitan